NEW YORK, Nov. 11, 2013
/PRNewswire/ -- Morgan & Morgan announces that it is
investigating potential legal claims against the board of
directors of Santarus, Inc. ("Santarus" or the "Company") (NASDAQ:
SNTS) concerning the proposed acquisition of the Company by Salix
Pharmaceuticals, Ltd. ("Salix").
Under the terms of the proposed transaction, Santarus
stockholders will receive $32.00 in
cash for each share of Santarus owned, valuing the transaction at
approximately $2.6 billion.
If you own shares of Santarus and want more information about
the Santarus takeover investigation please contact George Pressly, Esq. at 1(800)
631-6234 or email George at
AskGeorge@morgansecuritieslaw.com.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law by Santarus' Board of Directors for not
acting in the best interest of the Company's shareholders in
connection with the sale process.
Morgan & Morgan is one of the nation's largest 200 law
firms. In addition to securities fraud, the firm also practices in
the areas of antitrust, personal injury, consumer protection,
overtime, and product liability. All of the Firm's legal
endeavors are rooted in its core mission: provide investor and
consumer protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar
outcome.
Contact:
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44th Street
Suite 2001
New York, NY 10036
1-800-631-6234
info@morgansecuritieslaw.com
SOURCE Morgan & Morgan